RecruitingNot Applicable

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

United States500 participantsStarted 2024-07-22

Plain-language summary

The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Confirmed Multiple Sclerosis (MS) diagnosis.
✓. Participants who have not received any BRIUMVI® (ublituximab-xiiy) infusion prior to study start. Participants who have been prescribed BRIUMVI® (ublituximab-xiiy) but have not yet received their first infusion on Day 1 of 150 milligrams (mg) can be included.

Exclusion criteria

✕. Have received any live or live-attenuated vaccines (including for varicella-zoster virus or measles) within 4 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration or any non-live vaccines within 2 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration.
✕. Any active infection (e.g., active Hepatitis B virus \[HBV\])
✕. Concurrent participation in any interventional MS trials, or planned concurrent treatment with other Multiple Sclerosis Disease Modifying Therapy (MS DMT) during the study period.

What they're measuring

Annualized Relapse Rate (ARR)

Timeframe: Up to Week 96

Trial details

NCT IDNCT06433752

SponsorTG Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-07-01

Contact for this trial

TG Therapeutics Clinical Support Team

1-877-575-8489 clinicalsupport@tgtxinc.com

View on ClinicalTrials.gov More Relapsing Multiple Sclerosis trials